MedTrace Logo

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

NCT04594642 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 227

Last updated 2026-04-29

No results posted yet for this study

Summary

This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non-Hodgkin lymphoma (B-NHL).

Conditions

Interventions

DRUG

AZD0486 IV

AZD0486 is a bispecific antibody targeting CD19 on tumor cells and CD3 on T-cells leading to T cell-mediated cytotoxicity of malignant B cells

Sponsors & Collaborators

Principal Investigators

  • David Sermer, MD · AstraZeneca

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-02
Primary Completion
2028-04-19
Completion
2028-04-19
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Japan
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04594642 on ClinicalTrials.gov